Elicio Therapeutics, Inc. (ELTX) Misses ITT DFS Primary Endpoint in Phase 2 AMPLIFY-7P
Elicio Therapeutics (ELTX) reported that its Phase 2 AMPLIFY-7P study for camupepimut did not meet the primary endpoint (HR 0.85). The company attributed this to baseline ctDNA imbalance and plans to discuss a revised Phase 3 strategy with the FDA.
How this was made
The 30-second read
Why it matters
The miss suggests near‑term price weakness but leaves room for a strategic Phase 3 redesign.
Market read
Primary biotech trial miss; relevant for traders with exposure to early‑stage oncology stocks.
What to watch
Baseline ctDNA imbalance could be addressed in future trials, mitigating the miss.
Background
Elicio Therapeutics announced Phase 2 results for camupepimut (ELI-002 7P).
Ticker impact
Phase 2 AMPLIFY-7P trial missed its primary DFS endpoint (HR 0.85).
downward pressure as investors reassess trial outlook
First disclosure of a negative Phase 2 result for a biotech; market typically reacts negatively to missed endpoints.
Market effects
May weigh on other early‑stage oncology biotech stocks.
Limited to US biotech sector.
Low global impact beyond biotech investors.
Counterpoint
Potential upside if the company can pivot to a refined Phase 3 design with regulatory support.
Key entities
- CompanyElicio Therapeutics, Inc.
Biotech firm developing camupepimut.
